Start here if you're new
what it is
Jade is a pre-revenue biotech trying to turn three autoimmune drug programs into one eventual approved medicine.
how it gets paid
Last year Jade Biosciences made n/a in revenue.
what just happened
The clearest takeaway is the -$6.64 quarterly EPS loss, because revenue is still effectively zero.
At a glance
n/a balance sheet
-$85.31 fy2024 eps est
n/a operating margin
1.4 beta
~$686M market cap
xvary composite: 35/100 — weak
What they do
Jade is a pre-revenue biotech trying to turn three autoimmune drug programs into one eventual approved medicine.
The closest thing Jade has to a moat is focus. It has 3 disclosed programs and just 4 employees, so your bet is on picking the right targets, not on a giant cost base. JADE101 is the lead shot, with a first-in-human trial expected in 2H 2025, so one clean data point can swing a $686M company.
How they make money
n/a
annual revenue
The products that matter
lead clinical program
JADE101
the asset doing the real work
JADE101 is the center of gravity here. If you want the short version of the stock, start there. Good data changes the story. Bad data ends most of it.
main catalyst
balance sheet support
cash and equivalents
$336M reported on mar 6, 2026
For a company with no operating revenue, cash is not a side note. It is time. It funds trials, delays dilution, and tells you how long management gets to keep making the case.
runway
second layer of the story
platform claim
still mostly narrative
Every early biotech wants to be more than one asset. Until the lead program works, that second act is mostly a slide, not a business line.
optionality
Key numbers
$1M
long-term debt
Jade has just $1M of long-term debt, equal to 0% of capital. Plain English: debt is not the thing that breaks your thesis here.
-$85.31
2024 EPS est.
EPS → loss per share → so what: the business is still burning cash hard while it waits for human trial data.
1.4
beta
Beta → how violently a stock moves versus the market → so what: you should expect sharper swings than the S&P 500.
4
employees
Four employees running a public biotech is the deadpan part. It keeps overhead low, but it leaves very little room for mistakes.
Financial health
n/a
strength
- balance sheet grade n/a
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $1M (0% of capital)
n/a — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for JBIO right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The clearest takeaway is the -$6.64 quarterly EPS loss, because revenue is still effectively zero.
This is still a pipeline company, not an operating business. Quarterly EPS improved from -$19.58 to -$6.64 within 2024, but the full-year estimated loss still landed at -$85.31.
-$6.64
q4 eps
-$85.31
fy2024 eps est.
n/a
operating margin
the number that mattered
The number that mattered was the -$85.31 full-year EPS estimate, because it reminds you this stock is being priced on future data, not current earnings power.
source: quarterly EPS history and company data, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
JBIO is not carrying five different ways to win. The story is concentrated: one lead program, one cash balance, and a stock that already tells you it can move violently.
med
JADE101 fails to clear the bar
If the lead dataset disappoints, the market will not spend a week debating nuance. Single-asset biotech usually gets repriced in one move because the asset was the thesis.
impact: the equity story shrinks fast because there is no diversified revenue base to soften the blow
med
cash burn starts telling the story before the science does
$336M in cash helps, but cash is a wasting asset in biotech. If timelines slip, the balance sheet goes from support beam to countdown clock.
impact: dilution risk moves from background issue to headline issue, and existing holders pay for the extra time
med
the stock keeps trading like a sentiment instrument
A beta of 1.4, price stability of 5 / 100, and a 52-week range of $7–$100 are not subtle. Even before the science resolves, the tape can lurch around on risk appetite, liquidity, and biotech mood swings.
impact: you can be directionally right on the asset and still get punished by timing
The kill criterion is straightforward. If JADE101 de-risks before financing pressure rises, the story improves. If financing pressure rises first, the stock starts acting like a capital-raise candidate, not a clean clinical setup.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next company update
Use the next update to answer one question: did management buy more time, or did it move the science closer to a decision point.
trend
JADE101 de-risking
This is still the card that matters most. If the program gets cleaner and the timeline tightens, the whole page reads differently.
risk
financing pressure
Watch for the moment cash stops being reassurance and starts being a countdown. That is usually when biotech shareholders learn patience has a price.
metric
cash versus market value
With $336M in cash against a ~$686M market cap, balance-sheet math already matters more than usual. If that ratio worsens before a clear catalyst, the bull case gets thinner.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak, there is no clean consensus telling you where the street thinks fair value sits.
risk profile
volatile
beta is 1.4 and price stability is 5 / 100. Translation: you should expect bigger swings than you would get from a mature drug company.
chart momentum
catalyst-driven
This name trades more on trial expectations and funding math than on smooth technical trends. Here is the thing: the chart follows the calendar.
earnings predictability
40 / 100
That score is weak because there is no stable operating base yet. Numbers move around when the business is still mostly R&D spend and clinical timing.
source: institutional data
Institutional activity
institutional ownership data for JBIO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$15
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive